Phaseline

Targets › TRAC

TRAC (T cell receptor alpha chain constant): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2026.

Constant region of T cell receptor (TR) alpha chain. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, P01848)

Open in Phaseline: the race on TRAC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of BirminghamThymoglobulin
Polyclonal antithymocyte globulin (ATG) for T cell depletion; binds to T cell surface anti
TRACPhase 2Acute Myeloid LeukemiaAug 2027
Peking University People's HospitalReduced ATG plus mini PTCy
Combination of anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PT
TRAC, TRBC1, TRBC2Phase 2Myelodysplastic Syndrome–
Chiome BioscienceCBA-1535
T cell engager (bispecific antibody engaging 5T4 and CD3)
TRAC, 5T4Phase 1Solid TumorsDec 2026
Chinese PLA General HospitalAllogeneic CD19-STAR T cell
Allogeneic T cells with TRAC locus-inserted CD19-targeting synthetic TCR, with endogenous
CD19, TRACPhase 1Non-hodgkin Lymphoma,B CellMar 2027

Conditions

Myelodysplastic Syndrome (1) Non-hodgkin Lymphoma,B Cell (1) Solid Tumors (1) Acute Myeloid Leukemia (1)

Modalities

small molecule (2), mixed (2)

Companies

Peking University People's Hospital (1) Chinese PLA General Hospital (1) Chiome Bioscience (1) University of Birmingham (1)

Related targets

TRBC1 (1) TRBC2 (1) CD19 (1) 5T4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.